<DOC>
	<DOCNO>NCT02758964</DOCNO>
	<brief_summary>EARTH-TAVR diagnostic multicenter study evaluate occurrence extent cerebral embolization ( total new lesion volume ) patient TAVR versus 3 month TAVR .</brief_summary>
	<brief_title>Evaluation Cerebral Thrombembolism After TAVR</brief_title>
	<detailed_description>Calcific aortic valve stenosis common cause aortic stenosis ( AS ) among adult Europe United States . The prevalence moderate severe AS find age-dependent rise 0.02 % patient age 18-44 year 2.8 % patient age ≥ 75 year . Among patient prohibitive surgical risk , TAVR become treatment choice.The safety efficacy TAVR compare medical management SAVR demonstrate clinical trials.The composite rate all-cause death stroke 27 % 37 % TAVR patient 1 2 year , respectively.Even though part stroke occur peri-procedural period , patient remain risk stroke throughout first month procedure . EARTH-TAVR diagnostic multicenter study perform association GALILEO trial ( NCT02556203 ) , investigate cerebral embolization MRI neurocognitive testing patient undergo TAVR , treat anticoagulation ( Rivaroxaban/ASS ) DAPT ( Clopidogrel/ASS ) . GALILEO global multicenter , open-label , randomize , event-driven , active-controlled study compare rivaroxaban-based antithrombotic strategy antiplatelet-based strategy transcatheter aortic valve replacement ( TAVR ) optimize clinical outcome . Investigators aim investigate peri-interventional delayed cerebral embolization early period ( 3 month ) TAVR analyze association neurocognitive parameter cerebral embolization pattern patient different antithrombotic treatment regime .</detailed_description>
	<mesh_term>Embolism</mesh_term>
	<mesh_term>Aortic Valve Stenosis</mesh_term>
	<mesh_term>Intracranial Embolism</mesh_term>
	<criteria>Man woman 18 year age old Via iliofemoral subclavian access Provide write IC Atrial fibrillation ( AF ) , current previous , ongoing indication oral anticoagulant Treatment Any indication continue treatment oral anticoagulant ( OAC ) Known bleed diathesis ( limited active internal bleeding , clinically significant bleeding , platelet count ≤ 50,000/mm3 screening , hemoglobin level &lt; 8.5 g/dL , active peptic ulcer know gastrointestinal ( GI ) bleeding , history intracranial hemorrhage subdural hematoma ) Any indication dualantiplatelet therapy ( DAPT ) 3 month randomization ( coronary , carotid peripheral stent implantation ) Clinically overt stroke within last 3 month Planned coronary vascular intervention major surgery Severe renal impairment ( eGFR &lt; 30 mL/min/1.73 m2 ) dialysis , postTAVR unresolved acute kidney injury renal dysfunction stage 2 high Moderate severe hepatic impairment ( ChildPugh Class B C ) hepatic disease associate coagulopathy Any contraindication cerebral MRI , particular : nonMRIconditional pacemaker MRI conditional pacemaker &lt; 4 week implant metal fragment eye aneurysm clip brain severe claustrophobia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>TAVR</keyword>
	<keyword>TAVI</keyword>
	<keyword>Transcatheter Aortic Valve Replacement</keyword>
	<keyword>Intracranial Embolism</keyword>
</DOC>